TICKERNERD
Menu
IQVIQVHealthcare · Diagnostics & Research

IQV Stock Forecast: IQVIA Holdings, Inc. Price Predictions for 2026-2027

Last close, 4 Sept 2026
$268
−1.42% on the day

The 21 Wall Street analysts covering IQVIA Holdings, Inc. hold a median 12-month price target of $278 — +3.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 89 of 100 as at 7 Sept 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$44.1B
Ticker Nerd rank
89 / 100
Median analyst target
$278
Analysts covering
21
Revenue$4.4B+8.7% y/y
Operating income$569.0M
Net income$258.0M
Free cash flow$360.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+2.3%
1M
+17.3%
YTD
+18.8%
1Y
+45.5%
From 52W high
−1.4%
From 52W low
+70.9%
$157
$272
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

IQV stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores IQVIA Holdings, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 7 Sept 2026
89 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
88
Value
88
Volatility
76
Momentum
72
Quality
72
Growth
68
Issuance
68
Accruals
66
Size
6

Revisions (88): Analysts have, on balance, been raising their forecasts.

Accruals (66): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Size (6): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

IQV stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on IQV, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$150$200$250$300Oct 25Jan 26Apr 26Jul 26IQVHigh $300Median $278Low $240

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says21 analysts
18 Buy3 Hold0 Sell
Low $240Median $278High $300

The green dot is the last close — the median target sits +3.8% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 7 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
29 July 2026BairdMaintainsOutperform$252 → $287
29 July 2026BMO CapitalMaintainsOutperform$210 → $270
29 July 2026JP MorganMaintainsOverweight$225 → $285
29 July 2026RBC CapitalMaintainsOutperform$221 → $247
29 July 2026StifelMaintainsBuy$220 → $276
29 July 2026TD CowenMaintainsBuy$233 → $288
13 July 2026MizuhoMaintainsOutperform$215 → $230
13 July 2026MizuhoMaintainsOutperform—
1 July 2026BairdMaintainsOutperform—
17 June 2026Morgan StanleyDowngradeEqual-Weight—
8 Apr 2026Evercore ISI GroupMaintainsOutperform—
9 Mar 2026TD CowenUpgradeBuy—
6 Mar 2026BarclaysUpgradeOverweight—
3 Mar 2026RBC CapitalInitiatesOutperform—
19 Feb 2026Truist SecuritiesMaintainsBuy—
6 Feb 2026BarclaysMaintainsEqual-Weight—
6 Feb 2026CitigroupMaintainsNeutral—
6 Feb 2026JefferiesMaintainsBuy—
6 Feb 2026JP MorganMaintainsOverweight—
6 Feb 2026StifelMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. IQV appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

IQV vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 4 Sept 2026, IQVIA Holdings, Inc. returned +45.5% against +20.0% for the S&P 500, dividends included.

IQV vs S&P 500, last 12 monthsTotal return, rebased to 100
8090100110120130140150Oct 25Jan 26Apr 26Jul 26IQVS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

IQV analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+1.2%
Analysts raising
21
Analysts cutting
0
Fundamentals

IQVIA Holdings, Inc. (IQV) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
33.3×

Cheaper than 23% of US stocks

Price / sales
2.6×

Cheaper than 46% of US stocks

Price / book
7.1×

Cheaper than 14% of US stocks

EV / EBITDA
19.2×

Cheaper than 16% of US stocks

Growth & margins
Revenue growth (YoY)
8.7%

Higher than 48% of US stocks

Earnings growth (YoY)
−3.8%

Higher than 32% of US stocks

Gross margin
32.9%

Higher than 39% of US stocks

Operating margin
13.0%

Higher than 70% of US stocks

Net margin
8.1%

Higher than 66% of US stocks

Returns & dividend
Return on equity
22.8%

Higher than 84% of US stocks

Return on assets
5.1%

Higher than 77% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

IQVIA Holdings, Inc. (IQV) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • IQVIA Holdings, Inc. has a market value of $44.1B and an enterprise value of $58.4B.

  • Revenue in the twelve months to 30 June 2026: $17.0B. The latest quarter grew 8.7% year on year.

  • Net income over the same four quarters: $1.4B, a 8.1% net margin.

  • Diluted earnings per share, trailing twelve months: $8.06.

  • Free cash flow in the twelve months to 30 June 2026: $2.2B.

  • IQVIA Holdings, Inc. spent $1.2B on share buybacks in the twelve months to 30 June 2026.

  • Shares outstanding: 164.6M.

  • Trailing P/E: 33.3×; forward P/E: 18.5× — the forward figure prices analyst consensus estimates, not reported earnings.

  • IQVIA Holdings, Inc. employs 94,000 people — $181K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 8 Sept 2026

Data provided by Twelve Data

Peers

IQV vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDiagnostics & Research
CompanyMarket capTKN rank
IQVIQVIA Holdings, Inc.$44.1B
89
NTRANatera, Inc.$45.3B
79
AAgilent Technologies, Inc.$42.8B
87
IDXXIDEXX Laboratories, Inc.$42.8B
91
WATWaters Corp.$40.2B
51
ILMNIllumina, Inc.$33.0B
96
MTDMettler-Toledo International, Inc.$27.5B
92

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own IQVIA Holdings, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest IQV news & analysis

IQVIA's Predictive Clinical Development Provides Sponsors With Significant Efficiencies to Get Treatments to Market Faster

Business Wire · 3 Sept 2026positive

IQVIA announced the launch of IQVIA Predictive Clinical Development, an AI-powered approach designed to help life sciences sponsors reduce avoidable delays in clinical trials and bring new therapies to patients up to two years faster, in response to growing trial complexity.

Why it matters — This new AI-driven offering could strengthen IQVIA's competitive position in clinical research services and highlight its innovation in tackling industry-wide trial efficiency challenges.

IQVIA Wins Multiple Industry Awards for AI and Technology Innovation Across Life Sciences and Healthcare

Business Wire · 27 Aug 2026positive

IQVIA announced it received recognition this year from multiple independent industry awards programs for its use of AI. The recognition highlights AI applications that help healthcare and life sciences organizations improve decisions, strengthen regulated workflows, protect patient privacy and optimize clinical trial execution.

Why it matters — Awards recognition from independent programs underscores external validation of IQVIA's AI-driven technology offerings in life sciences and healthcare.

Why Is IQVIA (IQV) Up 5.6% Since Last Earnings Report?

Zacks Investment Research · 27 Aug 2026positive

IQVIA reported earnings 30 days ago, and its stock has risen 5.6% since that report. The article examines what may come next for the company's shares.

Why it matters — IQVIA watchers would care because the stock has gained ground since the recent earnings release, and the article assesses the outlook following that report.

Here's Why You Should Retain IQVIA Stock in Your Portfolio Now

Zacks Investment Research · 26 Aug 2026positive

IQVIA shares rose 21.7% over the past month, supported by its data assets, AI-enabled technology, and strong cash flow. The report notes the company still faces liquidity and pricing risks yet highlights these strengths as reasons to retain the stock.

Why it matters — IQV watchers would care because the item points to the company's key growth drivers and financial strengths that underpin the case for holding the stock amid ongoing liquidity and pricing risks.

IQVIA's AI-Enabled Clinical Decision Support Tool Wins 2026 AI Breakthrough Award for Predictive Modeling Solution of the Year

Business Wire · 20 Aug 2026positive

IQVIA announced that its AI-enabled Clinical Decision Support Tool, developed with Breakthrough T1D and powered by IQVIA Healthcare-grade AI, won the 2026 AI Breakthrough Award for Predictive Modeling Solution of the Year.

Why it matters — The award highlights IQVIA's AI capabilities and collaborative innovation in healthcare decision support, reinforcing its position in AI-driven clinical solutions.

FAQ

Frequently asked questions about IQV stock

What is the IQV stock price forecast for 2026-2027?

The 21 Wall Street analysts covering IQVIA Holdings, Inc. have a median 12-month price target of $278, with estimates ranging from $240 to $300. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is IQV stock a buy right now?

Of the 21 analysts covering IQVIA Holdings, Inc., 18 rate it a Buy, 3 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks IQVIA Holdings, Inc. 89 out of 100 across roughly 4,600 US stocks as at 7 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank IQV?

As at 7 Sept 2026, IQVIA Holdings, Inc. ranks 89 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (88 of 100).

Will IQV stock go up?

No one can know that. What the data says: the median 12-month target from 21 analysts implies +3.8% from the last close, and Ticker Nerd's factor model ranks IQVIA Holdings, Inc. 89 out of 100 as at 7 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the IQV stock forecast for 2030?

No analyst covering IQVIA Holdings, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for IQV are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $240 to $300 over the next 12 months.

How has IQV stock performed over the past year?

IQVIA Holdings, Inc. returned +45.5% over the 12 months to 4 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does IQVIA Holdings, Inc. do?

IQVIA Holdings Inc. is a global healthcare services and analytics company that supports the life sciences industry with clinical research services, commercial insights, and healthcare intelligence.

What is the latest news on IQV?

The most recent item we track (Business Wire, 3 Sept 2026): "IQVIA's Predictive Clinical Development Provides Sponsors With Significant Efficiencies to Get Treatments to Market Faster". IQVIA announced the launch of IQVIA Predictive Clinical Development, an AI-powered approach designed to help life sciences sponsors reduce avoidable delays in clinical trials and bring new therapies to patients up to two years faster, in response to growing trial complexity.

Company

About IQVIA Holdings, Inc.

IQVIA Holdings Inc. is a global healthcare services and analytics company that supports the life sciences industry with clinical research services, commercial insights, and healthcare intelligence. The company combines advanced data, technology solutions, and domain expertise to help pharmaceutical, biotechnology, medical device, and healthcare organizations improve clinical development, evidence generation, and commercial execution. Its core business spans technology and analytics solutions, research and development solutions, and contract sales and medical solutions, making it a key partner across the medical product lifecycle. IQVIA Holdings Inc. serves clients in major regions worldwide, including the Americas, Europe, Africa, and the Asia-Pacific, and plays an important role in turning health data into actionable insights for research, operations, and market access.

CEO Mr. Ari Bousbib · 94,000 employees · United States · https://www.iqvia.com